These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20723631)

  • 1. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
    Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
    Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
    N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
    Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated.
    Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA
    Vaccine; 2007 Jun; 25(23):4631-40. PubMed ID: 17478015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
    Fedson DS
    Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.
    Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F
    Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness.
    Simberkoff MS
    Semin Respir Infect; 1993 Dec; 8(4):294-9. PubMed ID: 7938926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
    Mangtani P; Roberts JA; Hall AJ; Cutts FT
    Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal vaccination.
    Williams RM
    Lippincotts Prim Care Pract; 1998; 2(6):625-33. PubMed ID: 9883157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal polysaccharide vaccine may not prevent hospitalization for pneumonia in elderly individuals.
    Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA
    Clin Infect Dis; 2007 Feb; 44(4):617; author reply 617-8. PubMed ID: 17260423
    [No Abstract]   [Full Text] [Related]  

  • 13. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay.
    Pírez MC; Algorta G; Cedrés A; Sobrero H; Varela A; Giachetto G; Montano A
    Pediatr Infect Dis J; 2011 Aug; 30(8):669-74. PubMed ID: 21407145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.
    Johnstone J; Marrie TJ; Eurich DT; Majumdar SR
    Arch Intern Med; 2007 Oct; 167(18):1938-43. PubMed ID: 17923592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
    Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
    Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
    Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
    Cai L; Uchiyama H; Yanagisawa S; Kamae I
    Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
    Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
    Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.